drugset
drugset / Trial / NCT00717340

A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer

NCT00717340 ↗

Phase 1 Completed 18 enrolled AVEO Pharmaceuticals, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a standard Phase 1b and 2a, multi-center, study design that will examine the safety, tolerability, maximum tolerated dose, and overall response rate of tivozanib (AV-951) and paclitaxel in a breast cancer.

Timeline

Start
2009-02
Primary completion
2011-01
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Tivozanib Small molecule 0.5 mg —
Subject Tivozanib Small molecule 1.5 mg —
Background Paclitaxel Small molecule 90 mg/m2 Intravenous

Indications

breast cancer